Proteomic analyses of methamphetamine (METH)-induced differential protein expression by immature dendritic cells (IDC)

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1774, Issue 4, 2007, Pages 433-442

  Reynolds, Jessica L ^a   Mahajan, Supriya D ^a   Sykes, Donald E ^a   Schwartz, Stanley A ^a   Nair, Madhavan P N ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b MIAMI CHILDREN'S HOSPITAL   (United States)

Author keywords

Difference Gel Electrophoresis (DIGE); HPLC MS MS; Immature dendritic cell (IDC); Methamphetamine

Indexed keywords

ANTIGEN P24; CATHEPSIN B; CELL PROTEIN; CHEMOKINE RECEPTOR CXCR3; GALECTIN 1; METHAMPHETAMINE; PEROXIREDOXIN; PROTEIN DISULFIDE ISOMERASE;

ARTICLE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; GEL ELECTROPHORESIS; GENE AMPLIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; LONG TERMINAL REPEAT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

DENDRITIC CELLS; GENE EXPRESSION REGULATION; HIV-1; HUMANS; METHAMPHETAMINE; PEROXIDASES; PROTEOMICS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33947694348     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2007.02.001     Document Type: Article

References (68)

1. National Drug Threat Assessment (NDTA) Summary Report (2005) Methamphetamine, www.usdoj.gov/ndic/pubs11/13846/meth.htm.
2. Substance Abuse and Mental Health Services Administration, Results from the 2005 National Survey on Drug Use and Health: National Findings, September 2006.
3. Frosch D., Shoptaw S., Huber A., Rawson R.A., and Ling W. Sexual HIV risk among gay and bisexual male methamphetamine abusers. J. Subst. Abuse Treat. 13 (1996) 483-486
4. Halkitis P.N., Parsons J.T., and Stirratt M.J. A double epidemic: crystal methamphetamine drug use in relations to HIV transmission among gay men. J. Homosex. 41 (2001) 17-35
5. Halkitis P.N., Fischgrund B.N., and Parsons J.T. Explanations for methamphetamine use among gay and bisexual men in New York City. Subst. Use Misuse 40 (2005) 1331-1345
6. Urbina A., and Jones K. Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin. Infect. Dis. 38 (2004) 890-894
7. Boddiger D. Metamphetamine use linked to rising HIV transmission. Lancet 365 (2005) 1217-1218
8. http://news.bbc.co.uk.go/pr/fr/-/2/hi/americas/4654503.
9. Baribaud F., Pohlmann S., Sparwasser T., Kimata M.T., Choi Y.K., Haggarty B.S., Ahmad N., Macfarlan T., Edwards T.G., Leslie G.J., Arnason J., Reinhart T.A., Kimata J.T., Littman D.R., Hoxie J.A., and Doms R.W. Functional and antigenic characterization of human, rhesus macaque, pigtailed macaque, and murine DC-SIGN. J. Virol. 75 (2001) 10281-10289
10. Geijtenbeek T.B., and van Kooyk Y. DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr. Top. Microbiol. Immunol. 276 (2003) 31-54
11. Pohlmann S., Leslie G.J., Edwards T.G., Macfarlan T., Reeves J.D., Hiebenthal-Millow K., Kirchhoff F., Baribaud F., and Doms R.W. DC-SIGN interactions with human immunodeficiency virus: virus binding and transfer are dissociable functions. J. Virol. 75 (2001) 10523-10526
12. Pohlmann S., Baribaud F., and Doms R.W. DC-SIGN and DC-SIGNR: helping hands for HIV. Trends Immunol. 22 (2001) 643-646
13. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90 (1997) 3245-3287
14. Steinman R.M., and Germain R.N. Antigen presentation and related immunological aspects of HIV-1 vaccines. AIDS 12SA (1998) S97-S112
15. Banchereau J., and Steinman R.M. DC and the control of immunity. Nature 392 (1998) 245-252
16. Nath A., Maragos W.F., Avison M.J., Schmitt F.A., and Berger J.R. Acceleration of HIV dementia with methamphetamine and cocaine. J. Neurovirol. 7 (2001) 66-71
17. Nath A., Hauser K.F., Wojna V., Booze R.M., Maragos W., Prendergast M., Cass W., and Turchan J.T. Molecular basis for interactions of HIV and drugs of abuse. J. Acquired Immune Defic. Syndr. 31S2 (2002) S62-S69
18. Markowitz M., Mohri H., Mehandru S., Shet A., Berry L., Kalyanaraman R., Kim A., Chung C., Jean-Pierre P., Horowitz A., La Mar M., Wrin T., Parkin N., Poles M., Petropoulos C., Mullen M., Boden D., and Ho D.D. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet (2005) 1031-1038
19. Nair M.P., Mahajan S.D., Schwartz S.A., Reynolds J., Whitney R., Bernstein Z., Chawda R.P., Sykes D., Hewitt R., and Hsiao C.B. Cocaine modulates dendritic cell-specific C type intercellular adhesion molecule-3-grabbing nonintegrin expression by dendritic cells in HIV-1 patients. J. Immunol. 174 (2005) 6617-6626
20. Dauer M.B., Obermaier J., Herten C., Haerle K., Pohl S., Rothenfusser M., Schnurr S., Endres S., and Eigler A. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170 (2003) 4069-4076
21. Dauer M., Pohl K., Obermaier B., Meskendahl T., Robe J., Schnurr M., Endres S., and Eigler A. Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation. Immunology 110 (2003) 38-47
22. Bender A.M., Sapp G., Schuler R., Steinman R.M., and Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196 (1996) 121-135
23. Turville S.G., Cameron P.U., Handley A., Lin G., Pöhlmann S., Doms R.W., and Cunningham A.L. Diversity of receptors binding HIV on dendritic cell subsets. Nat. Immunol. 3 (2002) 975-983
24. Frank, Kacani L., Stoiber H., Stossel H., Spruth M., Steindl F., Romani N., and Dierich M.P. Human immunodeficiency virus type 1 derived from cocultures of immature dendritic cells with autologous T cells carries T-cell-specific molecules on its surface and is highly infectious. J. Virol. 73 (1999) 3449-3454
25. Cameron P., Pope M., Granelli-Piperno A., and Steinman R.M. Dendritic cells and the replication of HIV-1. J. Leukocyte Biol. 59 (1996) 158-171
26. Theodore S., Cass W.A., Nath A., Steiner J., Young K., and Maragos W.F. Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction. Neurobiol. Dis. 23 (2006) 663-668
27. Lee Y.W., Hennig B., Yao J., and Toborek M. Methamphetamine induces AP-1 and NF-kappa B binding and transactivation in human brain endothelial cells. J. Neurosci. Res. 15 (2001) 583-591
28. Kalasinsky K.S., Bosy T.Z., Schmunk G.A., Reiber G., Anthony R.M., Furukawa Y., Guttman M., and Kish S.J. Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. Forensic Sci. Int. 116 (2001) 163-169
29. Klette K.L., Kettle A.R., and Jamerson M.H. Prevalence of use study for amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxy-amphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), and 3,4-methylenedioxy-ethylamphetamine (MDEA) in military entrance processing stations (MEPS) specimens. J. Anal. Toxicol. 30 (2006) 319-322
30. Takayasu T., Ohshima T., Nishigami J., Kondo T., and Nagaon T. Screening and determination of methamphetamine and amphetamine in the blood, urine and stomach contents in emergency medical care and autopsy cases. J. Clin. Forensic Med. 2 (1995) 25-33
31. Schepers R.J.F., Oyler J.M., Joseph R.E., Cone E.J., Moolchan E.T., and Huestis M.A. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin. Chem. 49 (2003) 121-132
32. Secchiero P., Zella D., Curreli S., Mirandola P., Capitani S., Gallo R.C., and Zauli G. Engagement of CD28 modulates CXC chemokine receptor 4 surface expression in both resting and CD3-stimulated CD4+ T cells. J. Immunol. 164 (2000) 4018-4024
33. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159
34. Shively L., Chang L., LeBon J.M., Liu Q., Riggs A.D., and Singer-Sam J. Real-time PCR assay for quantitative mismatch detection. BioTechniques 34 (2003) 498-502
35. Mahajan S., Schwartz S., and Nair M.P. Immunological assays for chemokine detection in vitro culture of CNS cells. Biol. Proced. Online 5 (2003) 90-102
36. http://www1.amershambiosciences.com/aptrix/upp00919.nsf/Content/Proteomics+DIGE+Protocols.
37. Tonge R., Shaw J., Middleton B., Rowlinson R., Rayner S., Young J., Pognan F., Hawkins E., Currie I., and Davison M. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics (2001) 377-396
38. Lilley K.S., and Friedman D.B. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev. Proteomics 1 (2004) 401-409
39. Wessel D., and Flugge U.I. Method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal. Biochem. 138 (1984) 141-143
40. Breci L., Hattrup E., Keeler M., Letarte J., Johnson R., and Haynes P.A. Comprehensive proteomics in yeast using chromatographic fractionation, gas phase fractionation, protein gel electrophoresis, and isoelectric focusing. Proteomics 5 (2005) 2018-2028
41. Gharahdaghi F., Weinberg C.R., Meagher D.A., Imai B.S., and Mische S.M. Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis 20 (1999) 601-605
42. Cooper B., Eckert D., Andon N.L., Yates J.R., and Haynes P.A. Investigative proteomics: identification of an unknown plant virus from infected plants using mass spectrometry. J. Am. Soc. Mass Spectrom. 14 (2003) 736-741
43. Wilm M.A., Shevchenko A., Houthaeve T., Breit S., Schweigerer L., Fotsis T., and Mann M. Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. Nature 379 (1996) 466-469
44. Haynes P.A., Gygi S.P., Figeys D., and Aebersold R. Proteome analysis: biological assay or data archive?. Electrophoresis 19 (1998) 1862-1871
45. Andon N.L., Hollingworth S., Koller A., Greenland A.J., Yates J.R., and Haynes P.A. Proteomic characterization of wheat amyloplasts using identification of proteins by tandem mass spectrometry. Proteomics 2 (2002) 1156-1168
46. Ellis R.J., Childers M.E., Cherner M., Lazzaretto D., Letendre S., and Grant I. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J. Infect. Dis. 188 (2003) 1820-1826
47. Bagasra O., and Pomerantz R.J. Human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells in the presence of cocaine. J. Infect. Dis. 168 (1993) 1157-1164
48. Gekker G., Hu S., Wentland M.P., Bidlack J.M., Lokensgard J.R., and Peterson P.K. Kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells. J. Pharmacol. Exp. Ther. 309 (2004) 600-606
49. Peterson P.K., Gekker G., Chao C.C., Schut R., Molitor T.W., and Balfour Jr. H.H. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor-beta. J. Immunol. 146 (1991) 81-84
50. Peterson P.K., Gekker G., Chao C.C., Schut R., Verhoef J., Edelman C.K., Erice A., and Balfour Jr. H.H. Cocaine amplifies HIV-1 replication in cytomegalovirus-stimulated peripheral blood mononuclear cell cocultures. J. Immunol. 149 (1992) 676-680
51. Peterson P.K., Gekker G., Schut R., Hu S., Balfour Jr. H.H., and Chao C.C. Enhancement of HIV-1 replication by opiates and cocaine: the cytokine connection. Adv. Exp. Med. Biol. 335 (1993) 181-188
52. Gavrilin M.A., Mathes L.E., and Podell M. Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J. Neurovirol. 8 (2002) 240-249
53. Bobkov A.F., Selimova L.M., Khanina T.A., Zverev S.Y., Pokrovsky V.V., Weber J.N., Bobkov E.N., and Rylkov A.V. Human immunodeficiency virus type 1 in illicit-drug solutions used intravenously retains infectivity. J. Clin. Microbiol. 43 (2005) 1937-1939
54. Elola M.T., Chiesa M.E., Alberti A.F., Mordoh J., and Fink N.E. Galectin-1 receptors in different cell types. J. Biomed. Sci. 12 (2005) 13-29
55. Almkvist J., and Karlsson A. Galectins as inflammatory mediators. Glycoconjugate J. 19 (2004) 575-581
56. Scott K., and Weinberg C. Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconjugate J. 1 (2004) 467-477
57. Ouellet M., Mercier S., Pelletier I., Bounou S., Roy J., Hirabayashi J., Sato S., and Tremblay M.J. Galectin-1 acts as a soluble host factor that promotes HIV-1 infectivity through stabilization of virus attachment to host cells. J. Immunol. 174 (2005) 4120-4126
58. Ryser H.J., and Fluckiger R. Progress in targeting HIV-1 entry. Drug Discov. Today 10 (2005) 1085-1094
59. Ryser H.J., Levy E.M., Mandel R., and DiSciullo G.J. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4559-4563
60. Barouche R., Lortat-Jacob H., Jones I.M., and Fenouillet E. Glycosaminoglycans and protein disulfide isomerase-mediated reduction of HIV Env. Mol. Pharmacol. 67 (2005) 1111-1118
61. Markovic I., Stantchev T.S., Fields K.H., Tiffany L.J., Tomic M., Weiss C.D., Broder C.C., Strebel K., and Clouse K.A. Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood 103 (2004) 1586-1594
62. Gallina A., Hanley T.M., Mandel R., Trahey M., Broder C.C., Viglianti G.A., and Ryser H.J. Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. J. Biol. Chem. 277 (2002) 50579-50588
63. Fenouillet E., Barbouche R., Courageot J., and Miquelis R. The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 cell binding. J. Infect. Dis. 183 (2001) 744-752
64. Jolly C., Kashefi K., Hollinshead M., and Sattentau Q.J. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J. Exp. Med. (2004) 283-293
65. Feng Y., and Walsh C.A. The many faces of filamin: a versatile molecular scaffold for cell motility and signaling. Nat. Cell Biol. 6 (2004) 1034-1038
66. Tadokoro S., Shattil S.J., Eto K., Tai V., Liddington R.C., de Pereda J.M., Ginsberg M.H., and Calderwood D.A. Talin binding to integrin beta tails: a final common step in integrin activation. Science 302 (2003) 103-106
67. Rhee S.G., Chae H.Z., and Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radical Biol. Med. 38 (2005) 1543-1552
68. Geiben-Lynn R., Kursar M., Brown N.V., Addo M.M., Shau H., Lieberman J., Luster A.D., and Walker B.D. HIV-1 antiviral activity of recombinant natural killer cell enhancing factors, NKEF-A and NKEF-B, members of the peroxiredoxin family. J. Biol. Chem. 278 (2003) 1569-1574